Satellos Bioscience Inc.
For the period ended Jul 8, 2026. Filed Jul 8, 2026.
View on SEC.govAbout this filing
What a company based outside the US has published at home or sent to its shareholders. It is how many foreign companies share results and news between annual reports.
Jul 8, 2026 · Filed Jul 8, 2026
Use the contents to explore the available documents and sections.
Contents
EX-99.1 · Additional supporting measures:
Additional supporting measures:
Mean CK declined 38% from CL-101 baseline (2130 u/l) through month 6 in TRAILHEAD (1315 u/l).
Mean PUL2.0 (Performance of the Upper Limb 2.0) increased by one point in two participants and remained stable in two participants from TRAILHEAD baseline through month 6. In the natural history of DMD, upper limb function is generally expected to decline over time.
Mean PedsQL-MFS scores, a patient reported quality-of-life measure designed to quantify fatigue and adapted for adults, increased 6.94 points from CL-101 baseline (71.53 pts.) to month 6 in TRAILHEAD (78.47 pts.).
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.